Catheter Precision Inc

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catheter Precision, Inc. engages in the design, manufacture and sale of medical devices and technologies for cardiac electrophysiology. It offers the Amigo Remote Catheter System for accurate positioning, manipulation, and stable control of catheters for use by electrophysiologists in the diagnosis and treatment of abnormal heart rhythms. The company was founded by David Jenkins in September 2002 and is headquartered in Fort Mill, SC.

FORT MILL, SC / ACCESSWIRE / May 6, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q1 Financials, Operational Report for the quarter ending March 31, 2024. Operational highlights of the first quarter and early second quarter 2024 include the following: Submission of LockeT for CE Mark approval, which is expected in Q3 2024.

Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report

FORT MILL, SC / ACCESSWIRE / May 1, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), is pleased to announce and welcome Marie-Claude Jacques as Chief Commercial Officer. Marie-Claude will be responsible for the commercialization team including sales and marketing to develop new business opportunities and improve the customer experience.

Catheter Precision, Inc. (NYSE-American: VTAK) Announces New Chief Commercial Officer

FORT MILL, SC / ACCESSWIRE / April 24, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) ($VTAK), a leading MedTech company specializing in innovative products for cardiac electrophysiology, including its VIVO™ and LockeT products, announces that is has received its first purchase order (PO) for LockeT from an HCA Healthcare facility. With over $64 Billion in revenue in 2023, HCA Healthcare is one of the nation's leading providers of healthcare services, comprised of 186 hospitals with approximately 2,400 sites of care in 20 states and the United Kingdom.

Catheter Precision, Inc. (VTAK) Announces Receipt of First Purchase Order for LockeT from HCA Healthcare Facility

FORT MILL, SC / ACCESSWIRE / April 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a leading MedTech company specializing in innovative products for cardiac electrophysiology, including its VIVO and LockeT products, has announced a major expansion in its business development team. The company is bolstering its sales team with experienced industry veterans to drive growth and market penetration.

Catheter Precision, Inc. (NYSE-American:VTAK) Expands Sales Team; Expects Corresponding Rise in Revenue Over the Near Term; Anticipates Breakeven by End of Year

FORT MILL, SC / ACCESSWIRE / April 1, 2024 / Catheter Precision, Inc. (NYSE-American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q4 and Annual Financials, Operational Report for year ending 2023, showcasing substantial revenue growth rate year over year. Additionally, the company makes strides, achieves milestones, etc.

Catheter Precision, Inc. (NYSE American:VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending December 31, 2023

FORT MILL, SC / ACCESSWIRE / March 19, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on electrophysiology products, is honored to be sponsor a session at the upcoming Monaco USA Arrhythmia Course taking place March 21-23 in Monaco. The course is organized by co-directors, Professor Nadir Saoudi, Professor of Cardiology and Chief of the Cardiology Section at the Princess Grace Medical Centre in Monaco, and Dr. Francis Marchlinski, Professor of Medicine and Director of Electrophysiology at the University of Pennsylvania, Philadelphia, Pennsylvania.

Catheter Precision, Inc. (NYSE American:VTAK) to Sponsor the Monaco USA Arrhythmia Course

FORT MILL, SC / ACCESSWIRE / March 14, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on innovative electrophysiology products, announced that VIVO was used in five procedures for the first time in Qatar at Hamad Medical Corporation Heart Hospital in Doha. Hamad Medical Corporation (HMC) is the main provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East.

Catheter Precision, Inc. (NYSE American:VTAK) Announces the First use of VIVO in Qatar

FORT MILL, SC / ACCESSWIRE / March 11, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on electrophysiology products, announced that LockeT was used for the first time outside of the United States at Hamad Medical Corporation Heart Hospital in Doha, Qatar. Hamad Medical Corporation (HMC) is the main provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East.

Catheter Precision, Inc. (NYSE American: VTAK) Announces the First use of LockeT Outside of the United States

FORT MILL, SC / ACCESSWIRE / February 28, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a U.S. based medical device company focused on novel electrophysiology products, announced that VIVO was used for the first time on a pediatric patient in Turkey. The Company recently announced its new distribution partnership with Ege Artimi in Turkey in January.

Catheter Precision, Inc. (NYSE American:VTAK) Announces the First Use of VIVO With a Pediatric Patient in Turkey

FORT MILL, SC / ACCESSWIRE / February 26, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on novel electrophysiology products, announced that the Company is showcasing their LockeT suture closure device at the International Symposium on Left Atrial Appendage. The annual ISLAA conference is taking place at the Intercontinental New York Times Square in New York City from March 1 - 2, 2024.

Catheter Precision, Inc. (NYS American:VTAK) Announces Attendance at the International Symposium on Left Atrial Appendage

FORT MILL, SC / ACCESSWIRE / February 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US-based medical device company focused on novel electrophysiology products, announced that the clinical data from the first LockeT study will be presented at the Western Atrial Fibrillation Symposium (Western AFib). The 17th annual Western AFib conference is taking place in Park City, Utah from February 23 - 24, 2024.

Catheter Precision, Inc. Announces the Presentation of the First Clinical Data on LockeT

FORT MILL, SC / ACCESSWIRE / January 29, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products is participating in the AF Symposium conference. The AF Symposium is taking place in Boston, Massachusetts from February 1-3, at the Omni Seaport Hotel.

Catheter Precision, Inc. Participates in AF Symposium

FORT MILL, SC / ACCESSWIRE / January 25, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced that it has signed a new distributor for Turkey for VIVO, a non-invasive 3D localization system. Ege Artimi, located in Izmir, Turkiye (Turkey), was founded in 2014 and specializes in importing and providing clinical support to cardiology products.

Catheter Precision, Inc. (VTAK) Secures New Distributor for VIVO in Turkey

FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.

Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced that it has completed a distribution agreement with Supri Artigos Medico Artigos Hospitalares Ltda ("SUPRI") for LockeT in Brazil. Supri, located in Sao Palo, Brazil, is an importer and distributor of medical and hospital articles and equipment and was founded 2005 and specializes in the cardiology and electrophysiology field.

Catheter Precision, Inc. (VTAK) Secures New Distributor in Brazil for LockeT

FORT MILL, SC / ACCESSWIRE / January 17, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a leader in non-invasive 3D mapping for ventricular arrhythmias, announced that their VIVO System was highlighted as part of a case study in the current issue of EP Lab Digest. EP Lab Digest is an educational, monthly publication dedicated to electrophysiology with both print and online content.

Catheter Precision's VIVO System Featured in Electrophysiology Publication

(This release corrects the release that was posted earlier on January 11, 2024 to update company information) FORT MILL, SC / ACCESSWIRE / January 11, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announces that its CEO and Chairman, Mr. David Jenkins, [and/or one or more of his affiliated entities] has been authorized to purchase up to 500,000 shares of the Company's common stock in open market transactions across multiple trading days.

CORRECTION: Catheter Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares

FORT MILL, SC / ACCESSWIRE / January 11, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announces that its CEO and Chairman, Mr. David Jenkins, [and/or one or more of his affiliated entities] has been authorized to purchase up to 500,000 shares of the Company's common stock in open market transactions across multiple trading days.

Cather Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares

FORT MILL, SC / ACCESSWIRE / January 10, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights and unaudited preliminary annual and fourth quarter results of 2023. Unaudited preliminary results of the fourth quarter and year ended December 31, 2023, include the following: Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively.

CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results

FORT MILL, SC / ACCESSWIRE / January 3, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, today announced changes to the executive management and board of directors, including a change to the Chief Financial Officer. Mr. Passey's employment was terminated effective December 31, 2023.

Catheter Precision, Inc. (VTAK) Announces Changes to Executive Management and Board of Directors

New Patents Demonstrate Uniqueness of the Closure Product Design FORT MILL, SC / ACCESSWIRE / January 2, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced today that Great Britain and the European Market have allowed two new patents (No. 6288592 and No.

Catheter Precision, Inc. (VTAK) Receives Additional Patents for LockeT in Great Britain and the European Market

FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023. Highlights of the third quarter include the following: Received approval for first purchase in France.

Catheter Precision, Inc. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q

FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023. Highlights of the second quarter include the following: US sales team was assembled, trained, and is creating a pipeline.

CATHETER PRECISION, INC. Reports Filing of 10-Q and Second Quarter Results of Operations

FORT MILL, SC / ACCESSWIRE / December 5, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) is pleased to announce that it has been invited to present at the Emerging Growth Conference on December 6, 2023. Catheter Precision, Inc. (NYSE American: VTAK) will be discussing VIVO™, its innovative non-invasive, 3D mapping system that enables physicians to identify the origin of ventricular cardiac arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time.

Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Emerging Growth Conference on December 6, 2023

FORT MILL, SC / ACCESSWIRE / November 20, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a pioneering medical technology firm headquartered in the United States, specializing in electrophysiology devices, has proudly disclosed the successful conclusion of the inaugural VIVO cases in the region of South-Eastern Europe. VIVO, the Company's innovative 3D non-invasive imaging system, is used pre-procedurally to identify areas of interest for ventricular ablation and aid in pre-procedure planning to reduce procedure time and aid in procedural accuracy.

News for Catheter Precision Inc Stock (VTAK)